免疫治疗在中晚期复发、转移性宫颈癌患者中的应用效果  

Application effect of immunotherapy in patients with advanced recurrent and metastatic cervical cancer

作　　者：邹美燕[1] 吴海龙[2] 姚心雨 安云婷[1] ZOU Meiyan;WU Hailong;YAO Xinyu;AN Yunting(Department of Oncology,Jiangxi Maternal and Child Health Hospital,Nanchang 330006,Jiangxi,China;Department of Imaging,the Second Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi,China)

机构地区：[1]江西省妇幼保健院肿瘤科,南昌330006 [2]南昌大学第二附属医院影像科,南昌330006

出　　处：《癌症进展》2025年第4期421-424,共4页Oncology Progress

基　　金：江西省卫生健康委科技计划项目(202310952)。

摘　　要：目的探讨免疫治疗在中晚期复发、转移性宫颈癌患者中的应用效果。方法选取23例中晚期复发、转移性宫颈癌患者,分析患者的治疗情况、临床疗效、不良反应发生情况及分级。结果23例中晚期复发、转移性宫颈癌患者均接受免疫治疗,10例患者接受化疗+卡瑞利珠单抗治疗,8例患者接受放化疗+卡瑞利珠单抗治疗,5例患者接受化疗+卡瑞利珠单抗+抗血管生成治疗。9例患者疗效评估为完全缓解(CR),6例患者为部分缓解(PR),4例患者为疾病稳定(SD),4例患者为疾病进展(PD);客观缓解率(ORR)为65.22%,疾病控制率(DCR)为82.61%。23例宫颈癌患者随访5~46个月,中位随访时间为28个月;无进展生存期(PFS)为1~39个月,中位PFS为17.5个月;总生存期(OS)为5~43个月,中位OS为23个月。23例患者中,7例患者因疾病进展或其他原因死亡,其余16例患者中,3例患者影像学评估为PR后停药,5例患者无瘤生存,8例患者带瘤生存。免疫治疗期间,中晚期复发、转移性宫颈癌患者主要为轻、中度不良反应(1~2级),以发热乏力、恶心呕吐为主,严重不良反应(3~4级)总发生率为26.09%。结论免疫治疗应用于中晚期复发、转移性宫颈癌患者中的疗效和安全性良好。Objective To explore the application effect of immunotherapy in patients with advanced recurrent and metastatic cervical cancer.Method A total of 23 patients with advanced recurrent and metastatic cervical cancer were selected.The treatment conditions,clinical efficacy,occurrence and grading of adverse reactions of the patients were analyzed.Result All 23 patients with advanced recurrent and metastatic cervical cancer received immunotherapy.Among them,10 patients received chemotherapy combined with camrelizumab,8 patients received chemoradiotherapy combined with camrelizumab,and 5 patients received chemotherapy combined with camrelizumab and anti-angiogenic therapy.Nine patients achieved complete response(CR),6 patients achieved partial response(PR),4 patients had stable disease(SD),and 4 patients had progressive disease(PD).The objective response rate(ORR)was 65.22%,and the disease control rate(DCR)was 82.61%.The 23 patients with cervical cancer were followed up for 5 to 46 months,with a median follow-up time of 28 months.The progression-free survival(PFS)was 1 to 39 months,with a median PFS of 17.5 months.The overall survival(OS)was 5 to 43 months,with a median OS of 23 months.Among the 23 patients,7 patients died due to disease progression or other reasons.Among the remaining 16 patients,3 patients stopped treatment after achieving PR by imaging assessment,5 patients were tumor-free,and 8 patients survived with tumors.During immunotherapy,the main adverse reactions in patients with advanced recurrent and metastatic cervical cancer were mild to moderate(grade 1-2),mainly fever,fatigue,nausea and vomiting.The total incidence of severe adverse reactions(grade 3-4)was 26.09%.Conclusion Immunotherapy has good efficacy and safety in patients with advanced recurrent and metastatic cervical cancer.

关 键 词：免疫治疗 宫颈癌 卡瑞利珠单抗 

分 类 号：R737.33[医药卫生—肿瘤]